

Product Data Sheet

Product Name: RJS308 TFA

Cat. No.: GC80941

Chemical Properties

Cas. No.


Formula $C_{65}H_{76}F_3N_{13}O_{13}S$ M.Wt 1336.44

Solubility DMSO: 100 mg/mL (74.83 mM; Need ultrasonic) Storage Store at 4°C, away from moisture and light

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

RJS308 TFA is a selective Cyclophilin A (CypA) PROTAC degrader. RJS308 TFA induces ubiquitin-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

dependent CypA degradation by recruiting the VHL E3 ligase complex, and forms a ternary complex with CypA and VHL/elongin C/elongin B. RJS308 TFA exhibits anti- HIV-1 and anti- HCV activities. RJS308 TFA can be used in studies related to viral infections ^[1]. (Pink: Cyclophilin A ligand; Blue: VHL ligand; Black: linker).

In Vitro, RJS308 TFA binds to recombinant full-length human CypA in SPR binding assays with a KD value of 108 nM, and also binds to N-terminally truncated human CypB with a KD value of 320 nM^[1]. RJS308 TFA (0.01-10 µM; 0-6 days) degrades CypA in Jurkat cells^[1]. RJS308 TFA (1-5 µM; 48 h) exhibits anti-HIV-1 activity in primary activated human CD4+ T cells, and this activity depends on VHL-mediated CypA degradation^[1]. RJS308 TFA (1-5 µM; 48 h) exhibits anti-HCV activity in Huh7 human hepatocellular carcinoma cells, and this activity depends on VHL-mediated CypA degradation^[1].

References:

[1]. Newton LS, et al., Macrocyclic-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV. Nat Commun. 2025 Feb 10;16(1):1484.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA